Leukemia, Myelocytic, Acute

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

1 week ago talkbio0Tagged annual, Antibody-Drug Conjugates, Asymmetric Septal Hypertrophy, CD64-targeting ADC, Leukemia, Myelocytic, Acute, Leukemia, Myelomonocytic, Chronic, meeting, Monocytic leukemia, OncoPrecision, Resistance (Psychotherapeutic)

OncoPrecision; ONC001; CD64-targeting ADC; monocytic leukemia; acute myeloid leukemia; ASH Annual Meeting; antibody-drug conjugate; CMML; therapy resistance

FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

1 month ago talkbio0Tagged Acute leukemia, Antibody-Drug Conjugates, Approved, black-box warning, Chromosomal translocation, differentiation syndrome, KMT2A gene, Leukemia, Myelocytic, Acute, Menin Inhibitor, oncology drug approval, Revuforj, revumenib, SmithKline Beecham, Syndax, United States Food and Drug Administration

Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

2 months ago talkbio0Tagged Acquisition, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, BTN3A, butyrophilin superfamily, ImCheck Therapeutics, Immunotherapy, Ipsen, Leukemia, Myelocytic, Acute, Monoclonal Antibodies, Oncology Pipeline

Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A

Fierce Biotech Fundraising Tracker ’25: CHARM attracts $80M; Wugen reels in $115M

3 months ago talkbio0Tagged AI drug design, charmed, Drug Development, Leukemia, Myelocytic, Acute, Menin Inhibitor, NVIDIA, Series B funding, venture capital, Wugen

CHARM Therapeutics; AI drug design; menin inhibitor; acute myeloid leukemia (AML); Series B funding; venture capital; biotech fundraising; Wugen; NVIDIA; drug development

Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths

4 months ago talkbio0Tagged CDC7 protein, human, clinical trial halt, drug safety, Inhibitor, leukemia, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, patient deaths, Schrödinger, SGR-2921

Schrödinger; SGR-2921; leukaemia; acute myeloid leukaemia (AML); myelodysplastic syndromes (MDS); CDC7 inhibitor; clinical trial halt; patient deaths; drug safety

FDA restricts bluebird bio’s Skysona to CALD patients without suitable stem cell donors after higher blood cancer risk emerges

4 months ago talkbio0Tagged boxed, CALD, Cautionary Warning, Cerebral Adrenoleukodystrophy, Donor person, Elivaldogene autotemcel, gene therapy, Hematologic Neoplasms, HLA Match, label update, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, Safety, Skysona, United States Food and Drug Administration

FDA; bluebird bio; Skysona; elivaldogene autotemcel; eli-cel; cerebral adrenoleukodystrophy; CALD; hematologic malignancies; myelodysplastic syndrome (MDS); acute myeloid leukemia (AML); boxed warning; label update; postmarketing safety; HLA-matched donor; gene therapy safety

FDA tightens Skysona label, restricting use to CALD patients without alternative options due to increased blood cancer risk

4 months ago talkbio0Tagged boxed, CALD, Cautionary Warning, Cerebral Adrenoleukodystrophy, Elivaldogene autotemcel, gene therapy, Hematologic Neoplasms, HLA‑matched donor, labeling changes, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, Safety, Skysona, United States Food and Drug Administration

FDA; bluebird bio; Skysona; elivaldogene autotemcel; labeling changes; boxed warning; hematologic malignancy; myelodysplastic syndrome; acute myeloid leukemia; cerebral adrenoleukodystrophy; CALD; HLA‑matched donor; gene therapy safety; post‑marketing reports

Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff

7 months ago talkbio0Tagged 95%, gene therapy, Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular

Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

8 months ago talkbio0Tagged 32%, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, CAR-T, Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, Neoplasms, Reindeer, Staff, United States Food and Drug Administration

Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%

Orca’s cell therapy trounces traditional care in blood cancer phase 3, swimming into space’s ‘holy grail’

9 months ago talkbio0Tagged Acute lymphocytic leukemia, allogeneic hematopoietic stem cell transplant with purging, Leukemia, Myelocytic, Acute

allogeneic hematopoietic stem cell transplant with purging, Leukemia, Myelocytic, Acute, Acute lymphocytic leukemia